- Home
- RDN vs ERAS Comparison
RDN vs ERAS Comparison
Compare RDN & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RDN | ERAS |
|---|---|---|
| Founded | 1977 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.0B |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDN | ERAS |
|---|---|---|
| Price | $36.59 | $14.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $40.67 | $14.25 |
| AVG Volume (30 Days) | 1.2M | ★ 5.4M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | 5.61 | ★ 36.23 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $1,197,084,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.66 | N/A |
| P/E Ratio | $40.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $31.50 | $1.24 |
| 52 Week High | $38.84 | $24.28 |
Technical Indicators
Market Signals| Indicator | RDN | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 58.36 |
| Support Level | $31.96 | $13.46 |
| Resistance Level | $37.30 | $15.03 |
| Average True Range (ATR) | 0.75 | 1.04 |
| MACD | 0.24 | 0.21 |
| Stochastic Oscillator | 89.97 | 74.27 |
Price Performance
Historical ComparisonAbout RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.